Reuters logo
BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche
April 13, 2017 / 11:22 AM / 5 months ago

BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche

April 13 (Reuters) - Bristol-myers Squibb Co

* Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds, respectively

* Bristol-Myers Squibb Co - to receive a combined $470m upfront, along with potential milestone payments and tiered double-digit royalties from each company

* Bristol-Myers Squibb Co - under agreement to license BMS-986168, Biogen will pay to Bristol-Myers Squibb an upfront payment of $300 million

* Bristol-Myers Squibb Co - Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million

* Bristol-Myers Squibb says Roche will pay to Bristol-Myers Squibb an upfront payment of $170 million with potential milestone payments of up to $205 million

* Bristol-Myers Squibb - Biogen also will assume all remaining obligations to former stockholders of ipierian inc related to co’s acquisition of co in 2014 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below